February 10, 2026 · Form 4 insider transaction
Hansen Gwenn bought 42,875 shares of Nurix Therapeutics Inc at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 0 days after the transaction.
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.; The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.; RSUs do not expire; they either vest or are canceled prior to the vest date.